A PDE5 inhibitor (IC50s 3.6 and 3 nM for PDE5 activity in isolated rabbit platelets and human corpus cavernosum respectively) selective for PDE5 over PDE1 and PDE3 (IC50s 0.26 and 65 M respectively) reverses glucose-induced decreases in ANG1 expression and reduction of capillary-like tube formation by mouse dermal endothelial cells in vitro increases the number of functional blood vessels and regional blood flow in the sciatic nerve in a db/db mouse model of diabetic peripheral neuropathy increases ICP/MAP ratio in castrated rats at 20 mg/kg per day reduces cardiac arrest and resuscitation-induced increases in angiotensin II ACE ACE2 and various angiotensin receptors and increases survival in a porcine model of ischemia/reperfusion injury